GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InMed Pharmaceuticals Inc (FRA:MWG) » Definitions » Total Long-Term Liabilities

InMed Pharmaceuticals (FRA:MWG) Total Long-Term Liabilities : €0.39 Mil (As of Mar. 2025)


View and export this data going back to 2004. Start your Free Trial

What is InMed Pharmaceuticals Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. InMed Pharmaceuticals's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was €0.39 Mil.

InMed Pharmaceuticals Total Long-Term Liabilities Historical Data

The historical data trend for InMed Pharmaceuticals's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals Total Long-Term Liabilities Chart

InMed Pharmaceuticals Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.16 0.37 0.02 0.60

InMed Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 0.60 0.57 0.51 0.39

InMed Pharmaceuticals Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

InMed Pharmaceuticals Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

InMed Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InMed Pharmaceuticals Inc (FRA:MWG) » Definitions » Total Long-Term Liabilities
Comparable Companies
CPMD CANN MSTH FLHLF PRFX AKAN UPC OWPC CANB BUDZ ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
INM:USA MWG:Germany
Address
885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8
Website
https://www.inmedpharma.com
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.